Added to YB: 2026-06-15
Pitch date: 2026-06-10
RPRX [neutral]
Royalty Pharma plc
+6.92%
current return
Author Info
No bio for this author
Company Info
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.
Market Cap
$25.8B
Pitch Price
$54.95
Price Target
N/A
Dividend
1.62%
EV/EBITDA
23.01
P/E
31.09
EV/Sales
14.55
Sector
Pharmaceuticals
Category
growth
GS Healthcare Conference – Recap (Day 2 – Part 2) - Royalty Pharma plc
RPRX (overview): Royalty Pharma at $45.19. Unique model providing capital for future royalty streams, often cheaper than equity. Growth Score 84. Synthetic royalties mainstream (~$15B deployed in 5yrs). R&D partnerships w/ JNJ, Teva, Merck, Pfizer, Sanofi, Biogen. China out-licensed assets emerging. ~480 deals reviewed last yr, 2x vs 5yrs ago.
Read full article (1 min)